Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website

Nektar Therapeutics

Nektar Therapeutics reported $6.4M in Interest Expense on Debt for its fiscal quarter ending in March of 2023.

Interest Expense On Debt Change
Amgen AMGN:US USD 543M 128M
Baxter International BAX:US USD 127M 2M
BioCryst Pharmaceuticals BCRX:US USD 27.4M 938K
Biogen BIIB:US USD 62.5M 7.7M
Bristol-Myers Squibb BMY:US USD 288M 6M
Eli Lilly LLY:US USD 102.8M 18.8M
Esperion Therapeutics ESPR:US USD 14.39M 58K
Gilead Sciences GILD:US USD 230M 3M
Halozyme Therapeutics HALO:US USD 4.54M 27K
Immunogen IMGN:US USD 853K 118K
Incyte Corp INCY:US USD 469K 198K
Ionis Pharmaceuticals IONS:US USD 1.61M 123K
Ironwood Pharmaceuticals IRWD:US USD 1.53M 1000
Karyopharm Therapeutics KPTI:US USD 5.76M 127K
Nektar Therapeutics NKTR:US USD 6.4M 796K
Neurocrine Biosciences NBIX:US USD 1.1M 0
Novartis NOVN:VX USD 211M 8M
Pfizer PFE:US USD 318M 5M
Roche Holding ROG:VX CHF 348M 92M
Sarepta Therapeutics SRPT:US USD 6.32M 365K
Teva Pharmaceutical Industries Ltd TEVA:IT USD 260M 23M